Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc.

The much-touted arrival of "precision medicine" promises tailored technologies that help individuals and may also reduce health care costs. New research shows how pregnancy screening can meet both of ...

Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-NASHVILLE, Tenn., June ...

Researchers found that maternal plasma cell-free DNA methylation patterns in late pregnancy were associated with later autism ...

AUSTIN, Texas, April 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived ...

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of ...

Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...

AUSTIN, Texas, April 22, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera donor-derived, ...

Pirche AG, a leader in digital molecular risk assessment, today announced a new collaboration to advance the field of transplant medicine and immunosuppression. In a strategic collaboration with ...

Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...

Cell-free DNA (cfDNA) are small pieces of genomic DNA that have escaped into the bloodstream either through active release by the cell or are remnants of a terminated cell. In recent years, ...